- Home
- CHRS vs SAVA Comparison
CHRS vs SAVA Comparison
Compare CHRS & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- SAVA
- Stock Information
- Founded
- CHRS 2010
- SAVA 1998
- Country
- CHRS United States
- SAVA United States
- Employees
- CHRS N/A
- SAVA N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- SAVA Biotechnology: Pharmaceutical Preparations
- Sector
- CHRS Health Care
- SAVA Health Care
- Exchange
- CHRS Nasdaq
- SAVA Nasdaq
- Market Cap
- CHRS 134.4M
- SAVA 113.8M
- IPO Year
- CHRS 2014
- SAVA N/A
- Fundamental
- Price
- CHRS $1.07
- SAVA $2.55
- Analyst Decision
- CHRS Strong Buy
- SAVA Buy
- Analyst Count
- CHRS 4
- SAVA 3
- Target Price
- CHRS $5.38
- SAVA $111.50
- AVG Volume (30 Days)
- CHRS 2.0M
- SAVA 1.3M
- Earning Date
- CHRS 03-12-2025
- SAVA 03-07-2025
- Dividend Yield
- CHRS N/A
- SAVA N/A
- EPS Growth
- CHRS N/A
- SAVA N/A
- EPS
- CHRS N/A
- SAVA N/A
- Revenue
- CHRS $304,340,000.00
- SAVA N/A
- Revenue This Year
- CHRS $2.07
- SAVA N/A
- Revenue Next Year
- CHRS N/A
- SAVA N/A
- P/E Ratio
- CHRS N/A
- SAVA N/A
- Revenue Growth
- CHRS 44.19
- SAVA N/A
- 52 Week Low
- CHRS $0.66
- SAVA $2.23
- 52 Week High
- CHRS $2.65
- SAVA $42.20
- Technical
- Relative Strength Index (RSI)
- CHRS 39.03
- SAVA 41.47
- Support Level
- CHRS $1.06
- SAVA $2.25
- Resistance Level
- CHRS $1.16
- SAVA $2.36
- Average True Range (ATR)
- CHRS 0.08
- SAVA 0.14
- MACD
- CHRS 0.00
- SAVA 0.17
- Stochastic Oscillator
- CHRS 5.56
- SAVA 50.85
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.